3-Hydroxyisobutyrate (sodium salt)
(Synonyms: 3-HIB) 目录号 : GC42291An intermediate in the metabolism of valine
Cas No.:1219589-99-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
3-Hydroxyisobutyrate (3-HIB) is an intermediate in the metabolism of the branched-chain amino acid valine that is secreted by skeletal muscle. [1] [2] It dose-dependently increases fatty acid uptake by human umbilical vein endothelial cells (HUVECs) when used at concentrations ranging from 0.1 to 100 mM. [3] 3-HIB also increases fatty acid uptake and lipid accumulation in mouse skeletal muscle when administered in drinking water. The levels of 3-HIB in muscle are increased in db/db diabetic mice and in humans with diabetes. Human plasma levels are increased in obesity and correlate with a future risk of type 2 diabetes.[3] In addition, human serum levels of 3-HIB decrease by 2.5-fold immediately following an exercise regimen of 2.5 hours of running for three days. [1]
Reference:
[1]. Nieman, D.C., Shanely, R.A., Gillitt, N.D., et al. Serum metabolic signatures induced by a three-day intensified exercise period persist after 14 h of recovery in runners. J. Proteome Res. 12(10), 4577-4584 (2013).
[2]. Jang, C., Oh, S.F., Wada, S., et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat. Med. 22(4), 421-426 (2016).
[3]. Mardinoglu, A., Gogg, S., Lotta, L., et al. Elevated plasma levels of 3-hydroxyisobutyric acid are associated with incident type 2 diabetes. EBioMedicine 27, 151-155 (2018).
| Cas No. | 1219589-99-7 | SDF | |
| 别名 | 3-HIB | ||
| 化学名 | 3-hydroxy-2-methyl-propanoic acid, monosodium salt | ||
| Canonical SMILES | OCC(C)C([O-])=O.[Na+] | ||
| 分子式 | C4H7O3•Na | 分子量 | 126.1 |
| 溶解度 | 5 mg/ml in Ethanol | 储存条件 | Store at -20°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 7.9302 mL | 39.6511 mL | 79.3021 mL |
| 5 mM | 1.586 mL | 7.9302 mL | 15.8604 mL |
| 10 mM | 0.793 mL | 3.9651 mL | 7.9302 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet